TME has delivered its earnings and the market's verdict was swift — shares fell nearly 12% on August 11 to close at $8.72, extending a weekly loss of 9.4% and erasing the recovery that had carried the stock above $9.50 heading into the print.
The analyst response was immediate and pointed. China Renaissance downgraded TME to Hold from Buy on August 12, setting a $9.30 target — a level already above where the stock is trading. Mizuho, meanwhile, maintained its Outperform rating but cut its price target sharply from $18 to $15, reflecting a more cautious stance on the near-term outlook. Those two moves follow a longer pattern of target reductions: JP Morgan trimmed to $10 from $12 back in May, and UBS downgraded all the way to Neutral in March when it slashed its target from $26 to $13. The direction of travel across the Street has been consistently downward for months. At 16 buy ratings against 10 holds, the consensus technically remains constructive, but the weight of recent actions tells a different story. The mean price target of around $90 in the data should be treated with caution — it appears to reflect stale inputs or a pre-restructuring baseline, as TME is trading near $8.72, a fraction of that figure. More credible near-term anchors are the fresh targets from Mizuho ($15) and China Renaissance ($9.30). On valuation, the stock now trades at roughly 8.7x trailing earnings and 5.9x EV/EBITDA — both multiples compressing further after the week's move. Factor scores offer one bright spot: TME ranks in the 93rd percentile on EPS surprise and the 98th on dividend yield, while the EV/EBIT score of 80 suggests the market may be pricing in more stress than the underlying earnings quality warrants.
Short positioning tells a notably different story from the stock's sharp drop. Short interest has been falling, not rising — down 17% over the past month to around 25 million shares, and down another 15% in a single session on August 11 as shorts covered into the earnings move. The borrow market reinforces this picture: availability is exceptionally loose at 903%, meaning there are roughly nine shares available to lend for every one currently borrowed. The 52-week tightest point for availability was 470%, so the current level represents the loosest conditions of the past year. Cost to borrow is negligible at 0.47%, barely changed on the week. The ORTEX short score has dropped from 44.2 at the end of July to 40.1 now — a meaningful shift reflecting the combination of falling short interest and easing borrow pressure. None of this points to a classic earnings-driven short squeeze setup; instead, it looks like short sellers were reducing risk ahead of the print rather than piling in.
Options positioning had already been shifting before the earnings drop. The put/call ratio eased to 0.89, a full standard deviation below its 20-day average of 0.93 — meaning options traders were actually running lighter on downside protection than usual heading into the release. That PCR reading is near its 52-week low of 0.34 rather than the high of 1.01, suggesting the options market was not pricing in the magnitude of the move that occurred. Post-earnings, the next question for options traders is whether fresh protective flows rebuild, or whether the drop has reset expectations enough that the skew stabilises.
Ownership structure is worth keeping in mind. Tencent Holdings holds 52.7% of shares, giving it effective control and limiting the free float meaningfully. Spotify holds a further 9% stake, unchanged in the most recent filing. Among active institutional buyers, Invesco added 16 million shares through July, and ARGA Investment Management initiated a new position of 18 million shares through June — suggesting some value-oriented money has been accumulating even as the stock declined.
The next earnings event is scheduled for November 10. Between now and then, the key variables to watch are whether the fresh analyst downgrades trigger further institutional reweighting, and whether the post-earnings low near $8.72 holds as a base or becomes a new ceiling.
See the live data behind this article on ORTEX.
Open TME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
